IP Library Granted Patent US 7,851,636
Granted Patent B2
US 7,851,636 · App. 12/757,217 · Granted Dec 14, 2010

Heteroaryl-ureas and their use as glucokinase activators

Assignee: Novo Nordisk A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,636
App. No.
12/757,217
Granted
Dec 14, 2010
Kind
B2
Abstract

This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Claims (20)

1. {2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a salt thereof with a pharmaceutically acceptable acid or base.

2. A compound according to claim 1 , wherein the compound is {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]thiazol-5-ylsulfanyl}-acetic acid.

3. 3-{2-[3-Cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-propionic acid or a salt thereof with a pharmaceutically acceptable acid or base.

4. A compound according to claim 3 , wherein the compound is 3-{2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]thiazol-5-ylsulfanyl}-propionic acid.

5. 3-{2-[3-Cyclohexyl-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-propionic acid or a salt thereof with a pharmaceutically acceptable acid or base.

6. A compound according to claim 5 , wherein the compound is 3-{2-[3-cyclohexyl-3-(trans-4-methyl-cyclohexyl)-ureido]thiazol-5-ylsulfanyl}-propionic acid.

7. {2-[3-Cyclohexyl-3-(trans-4-methoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a salt thereof with a pharmaceutically acceptable acid or base.

8. A compound according to claim 7 , wherein the compound is {2-[3-cyclohexyl-3-(trans-4-methoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid.

9. 2-{2-[3-Cyclohexyl-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid or a salt thereof with a pharmaceutically acceptable acid or base.

10. A compound according to claim 9 , wherein the compound is 2-{2-[3-cyclohexyl-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-2-methyl-propionic acid.

11. A pharmaceutical composition comprising the compound or salt according to claim 1 , and a pharmaceutically acceptable carrier or excipient.

12. A pharmaceutical composition comprising the compound according to claim 2 , and a pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition comprising the compound or salt according to claim 3 , and a pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition comprising the compound according to claim 4 , and a pharmaceutically acceptable carrier or excipient.

15. A pharmaceutical composition comprising the compound or salt according to claim 5 , and a pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition comprising the compound according to claim 6 , and a pharmaceutically acceptable carrier or excipient.

17. A pharmaceutical composition comprising the compound or salt according to claim 7 , and a pharmaceutically acceptable carrier or excipient.

18. A pharmaceutical composition comprising the compound according to claim 8 , and a pharmaceutically acceptable carrier or excipient.

19. A pharmaceutical composition comprising the compound or salt according to claim 9 , and a pharmaceutically acceptable carrier or excipient.

20. A pharmaceutical composition comprising the compound according to claim 10 , and a pharmaceutically acceptable carrier or excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2021
From: NOVO NORDISK A/S
To: VTV THERAPEUTICS LLC
Reel/Frame 055584/0833 →
Priority Claims (3)
DK PA 2004 00013 · Jan 6, 2004 · national
DK PA 2004 01272 · Aug 23, 2004 · national
DK PA 2004 01897 · Dec 7, 2004 · national
Continuity (4)
Continuation 1218840200 · Aug 8, 2008
Continuation 1145333000 · Jun 14, 2006
Continuation PCTDK200500000200 · Jan 6, 2005
Related Publication 20100204288A1 · Aug 12, 2010